This is the authors' abstract. We don't add key points for this paper.
Background Bioidentical pellet hormone replacement therapy (HRT) has become one of the most prescribed types of HRT. This therapy involves the subcutaneous placement of a pellet (approximately the size of a grain of rice) in the hip or buttock. The pellet then releases hormones (estrogen, testosterone, and prohormones) into the blood stream over 3-6 months. The utility and safety of this method of HRT is understudied despite widespread use. Objective The aim of this study is to determine if subcutaneous pellet administration of bioidentical hormone replacement therapy (HRT) results in improved menopausal symptoms and serum estradiol/testosterone levels when compared to transdermal HRT. Study Design A retrospective observational cohort study of symptomatic menopausal women who underwent subcutaneous bioidentical pellet HRT containing estradiol and testosterone versus compounded transdermal lotion with estradiol and testosterone between 2018-2021. The first 200 women who were started on bioidentical pellet HRT containing estradiol and testosterone who met inclusion criteria were included. Likewise, the first 204 women who were started on transdermal lotion with estradiol and testosterone who met inclusion criteria were also included. Menopausal symptoms and serum hormone levels were collected at baseline as well as at 6 weeks if pellet HRT or 10 weeks with transdermal HRT. Long-term treatment satisfaction was compared between groups. Results Women on pellet therapy saw greater improvement in hot flashes than transdermal (-2.08 vs -1.03 p<0.001), as well as a significantly greater improvement in all other menopausal symptoms collected, except for depression. They also had larger increases in serum testosterone and larger decreases in FSH compared to women using lotion. There were no differences seen between the two groups in the development of adverse events/symptoms. Women initiated on pellet therapy were more likely to continue that therapy compared to those initiated on transdermal therapy (76% vs 59% p=0.019) and more likely to report that HRT treated their symptoms (89% vs 78% p<0.001). Conclusion Women receiving bioidentical hormone replacement therapy via subcutaneous pellet when compared to transdermal administration had greater improvement in menopausal symptoms without an increase in adverse events.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bailey et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: